Radiopharmaceutical practices are divided into large-scale industrial manufacturing and small-scale “in-house” hospital radiopharmacy unit. The recent evolution of nuclear medicine involves deep consequences in this ever-present regulatory state, and hospital radiopharmacy units cannot be considered as contract manufacturing organizations (CMO). This review provides an updated status report of the official (and non-official) guidelines supporting the regulations required to meet hospital and industry common radiopharmaceutical manufacturing standards to facilitate the current and future innovative radiopharmaceutical development.
Mendeley helps you to discover research relevant for your work.
CITATION STYLE
Faivre-Chauvet, A., Bourdeau, C., & Bourgeois, M. (2022). Radiopharmaceutical good practices: Regulation between hospital and industry. Frontiers in Nuclear Medicine, 2. https://doi.org/10.3389/fnume.2022.990330